Cannabis use in Parkinson's disease: Patient access to medical cannabis and physician perspective on product safety.

Autor: Griffith ST; College of Health Solutions, Arizona State University, Phoenix, AZ, United States; ASU-Banner Neurodegenerative Disease Research Center, Arizona State University, Tempe, AZ, United States., Conrow KD; School of Mathematical and Natural Sciences, Arizona State University, Glendale, AZ, United States., Go M; College of Arts and Sciences, University of Pennsylvania, Philadelphia, PA., McEntee ML; College of Health Solutions, Arizona State University, Phoenix, AZ, United States., Daniulaityte R; College of Health Solutions, Arizona State University, Phoenix, AZ, United States., Nadesan MH; School of Social and Behavioral Sciences, Arizona State University, Glendale, AZ, United States., Swinburne MR; Francis King Carey School of Laws, University of Maryland, Baltimore, MD, United States., Shill HA; Muhammad Ali Parkinson Center, Barrow Neurological Institute, Phoenix, AZ, United States., Leung MCK; College of Health Solutions, Arizona State University, Phoenix, AZ, United States; ASU-Banner Neurodegenerative Disease Research Center, Arizona State University, Tempe, AZ, United States; School of Mathematical and Natural Sciences, Arizona State University, Glendale, AZ, United States. Electronic address: mckleung@asu.edu.
Jazyk: angličtina
Zdroj: Neurotoxicology [Neurotoxicology] 2024 Jul; Vol. 103, pp. 198-205. Date of Electronic Publication: 2024 Jun 02.
DOI: 10.1016/j.neuro.2024.05.008
Abstrakt: The rate of medical cannabis use has increased in parallel with the number of states legalizing its use. Parkinson's disease (PD) patients are of particular concern due to their higher cannabis use rate than in the general US population (25-40 % PD patient cannabis users vs. ∼18 % in the general population), as well as their susceptibility to environmental contaminants in cannabis, including pesticides, toxic elements, solvents, microbes, and mycotoxins. In order to address the complex nature of this industry, we examined the changes in PD-related qualifying conditions in the U.S. from 2019 to 2023. We also conducted an online survey to gain insight into the knowledge, risk perceptions, and opinions regarding medical cannabis and contamination issues from physicians who treated PD patients. The number of states including PD-related qualifying conditions increased over the past 5 years from 28 to 36 states. These conditions included PD (increasing from 14 to 16 states), muscle spasms (14 to 24), anxiety (1 to 5), and pain (17 to 35). State-by-state comparisons revealed high variability in the language used to describe the different qualifying conditions. Online surveys were sent out to 45 neurologists and movement disorder specialists who primarily treated PD patients. The response rate was 44 % from nine states (AZ, CA, FL, MA, MN, WI, PA, IL, and NM). When asked if they were aware of any contaminants in cannabis products, we found that 65 % of the physicians were unaware of any contaminants commonly found in cannabis and only 25 %, 15 %, and 15 % of them were aware of pesticide, toxic element, and solvent contaminants, respectively. In their free-text opinion response on the health impact of cannabis-borne contaminants, "long-term effect" (35 %) and "comorbidities and PD prognosis" (40 %) were identified as the two most common themes. These results point to the need for further regulatory deliberation regarding risks and susceptibility to cannabis contaminants. Additionally, education is needed to inform physicians on cannabis safety issues. Further research will identify the implementation strategies to reduce contaminant exposure and protect patient health.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: